RxDoctor Payments Data

Polly Nobis, NP

Nurse Practitioner · Sterling, ILNPI 1063500304

Payments from drug & device makers

$1,723in general payments, 2019–2025

Across 89 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$382
  • Amgen$263
  • AstraZeneca$185
  • Boston Scientific$177
  • E.r. Squibb & Sons, L.L.C.$118
  • Boehringer Ingelheim$117
  • plus $480 from 9 others

What the payments were for

  • Food & beverage$1,723100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,723 in reported general payments places this provider in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$104,257
Medicare patients
496
Services billed
1,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$285,331
Repatha SureclickEvolocumab102$144,378
XareltoRivaroxaban65$76,826
EntrestoSacubitril/Valsartan45$51,926
Praluent PenAlirocumab27$38,733
Metoprolol Succinate463$5,963
Ezetimibe188$5,778
Atorvastatin Calcium418$4,420
ClopidogrelClopidogrel Bisulfate329$3,686
Potassium Chloride128$2,596
Rosuvastatin Calcium155$2,540
Metoprolol Tartrate280$2,338
Carvedilol255$2,224
Isosorbide Mononitrate ErIsosorbide Mononitrate138$1,707
Losartan Potassium164$1,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$65$285,331256 claims
NovartisEntresto$382$51,92645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Sterling

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →